Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.53 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.47 |
| ▸ | HTR3B | O95264 | 3/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706777 | 1.00 | HSD11B1 (0.53) | HSD11B1HSD11B2HTR3EHTR3BCHRNA7 | |
| SCHEMBL14157660 | 0.90 | HSD11B1 (0.54) | HSD11B1HSD11B2 | |
| SCHEMBL15706774 | 0.90 | HSD11B1 (0.54) | HSD11B1HSD11B2 | |
| SCHEMBL14157730 | 0.89 | HSD11B1 (0.53) | HSD11B1HSD11B2 | |
| SCHEMBL15706781 | 0.89 | HSD11B1 (0.53) | HSD11B1HSD11B2 | |
| SCHEMBL15706771 | 0.86 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL14157728 | 0.86 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL15706805 | 0.85 | HSD11B1 (0.51) | HSD11B1HSD11B2CHRNA7 | |
| SCHEMBL14157651 | 0.85 | HSD11B1 (0.51) | HSD11B1HSD11B2CHRNA7 | |
| SCHEMBL28094976 | 0.85 | HSD11B1 (0.48) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699560-B1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-04-20 | — | — | EP | claimed |
| US-9233957-B2 | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-12 | — | — | US | claimed |
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-08 | — | — | US | claimed |
| CN-103649066-A | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | SK BIOPHARMACEUTICALS CO LTD | 2014-03-19 | — | — | CN | claimed |
| EP-2699560-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2014-02-26 | — | — | EP | claimed |
| WO-2012169863-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-12-13 | — | — | WO | claimed |
| EP-2699560-B1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-9233957-B2 | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-12 | — | — | US | disclosed |
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-08 | — | — | US | disclosed |
| CN-103649066-A | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | SK BIOPHARMACEUTICALS CO LTD | 2014-03-19 | — | — | CN | disclosed |
| EP-2699560-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012169863-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885HSD11B2 4/4885HTR3E 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.